Trial Profile
A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- Sponsors Allergan
- 24 Nov 2013 New trial record